Condition
Perianal Crohns Disease
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Terminated1
Completed1
Active Not Recruiting1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05347095Phase 3Active Not Recruiting
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT06587646Not ApplicableRecruitingPrimary
VirtuAl Technology to Improve the Management of Perianal Crohn's (VAMP) - PROSPECTIVE
NCT01442363Phase 2TerminatedPrimary
A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease
NCT01915927Phase 1CompletedPrimary
Stem Cell Fistula Plug in Perianal Crohn's Disease
Showing all 4 trials